TwinStrand Biosciences develops and commercializes the duplex sequencing technology for DNA sequencing.
TwinStrand Biosciences improves the accuracy of DNA sequencing by >10,000 fold and allows detection of mutations that are invisible by other approaches, through its technology. Its technology, Duplex Sequencing, is based on research and has potential applications in a wide range of fields, including oncology, infectious disease, organ transplantation, reproductive and genetic health, and forensics.TwinStrand Biosciences holds an exclusive worldwide license to develop and commercialize Duplex Sequencing. It was founded in 2015 and is headquartered in Bellevue, Washington.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 13, 2017 | Series Unknown | $5.28M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Reference Capital | — | Series Unknown |